Simple Summary The benefit of programmed death-1/programmed death ligand-1 (PD-1/PD-
L1) immunotherapy, particularly of nivolumab, pembrolizumab and atezolizumab, in the …

Since the initial US FDA approval of an immune checkpoint inhibitor (ICI) for the treatment of
non-oncogene-driven non-small-cell lung cancer (NSCLC) nine years ago, this therapeutic …

Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with
various cancers. However, many patients are non-responders or develop resistance …

The haskap (Lonicera caerulea L., Caprifoliaceae) berry has been widely used in traditional
medicine in Kuril Islands, Russia, Japan, and China. Cyanidin-3-O-glucoside (C3G) is the …

Cancer patients with autoimmune disease (AID) are usually excluded from clinical trials
involving immune checkpoint inhibitors (ICIs). The available electronic databases were …

Background: Dysregulation of microRNAs (miRNAs) is associated with the pathogenesis of
non-small cell lung cancer (NSCLC). However, the mechanisms through which miR-182-5p …

Simple Summary Immunotherapy leads to highly variable responses in lung cancer patients.
We assessed the value of a blood-based test to predict which patients would benefit from …

Lung cancer is a malignancy with high incidence and mortality worldwide. Previous studies
have shown that the gut microbiome plays an important role in the development and …

The role of CD161+ CD127+ CD8+ T cells in non-small cell lung cancer (NSCLC) patients
with diabetes remains unexplored. This study determined the prevalence, phenotype, and …

Abstract Background Immune checkpoint inhibitors (ICIs) revolutionized non-small-cell lung
cancer (NSCLC) treatment. However, improving patients' selection for this therapy is …